Show simple item record

Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: results of a two-year open-label extension trial

dc.contributor.authorRaman, Subha V.
dc.contributor.authorHor, Kan N.
dc.contributor.authorMazur, Wojciech
dc.contributor.authorHe, Xin
dc.contributor.authorKissel, John T.
dc.contributor.authorSmart, Suzanne
dc.contributor.authorMcCarthy, Beth
dc.contributor.authorRoble, Sharon L.
dc.contributor.authorCripe, Linda H.
dc.date.accessioned2021-07-22T14:26:15Z
dc.date.available2021-07-22T14:26:15Z
dc.date.issued2017-02-20
dc.identifierhttps://doi.org/10.13016/ukx7-4b7f
dc.identifier.citationRaman, S.V., Hor, K.N., Mazur, W. et al. Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: results of a two-year open-label extension trial. Orphanet J Rare Dis 12, 39 (2017).en_US
dc.identifier.urihttp://hdl.handle.net/1903/27566
dc.description.abstractCardiomyopathy is a leading cause of morbidity and mortality in boys with Duchenne muscular dystrophy (DMD). We recently showed in a 12-month double-blind randomized controlled trial that adding eplerenone to background medical therapy was cardioprotective in this population. The objective of this study was to evaluate the safety and efficacy of longer-term eplerenone therapy in boys with DMD. Eleven subjects (phase 1 baseline median [range] age: 13 [7 – 25] years) from the original 12-month trial at a single participating center were enrolled. Importantly, those who entered the extension study who had been on eplerenone previously were significantly older than those who had originally been on placebo (median age 10.5 vs. 18.0 years, p = 0.045). During an additional 24-month open-label extension study, all boys received eplerenone 25 mg orally once daily to treat preclinical DMD cardiomyopathy, defined as evident myocardial damage by late gadolinium enhancement cardiac magnetic resonance (LGE) with preserved ejection fraction (EF). The threshold for potassium level, the primary safety measure, was not exceeded in any non-hemolyzed blood sample. Over 24 months, left ventricular (LV) systolic strain, a more sensitive marker whose more negative values indicate greater contractility significantly improved (median change -4.4%, IQR -5.8 to -0.9%) in younger subjects whereas older subjects’ strain remained stable without significant worsening or improvement (median change 0.2%, IQR -1.1 to 4.3%). EF and extent of myocardial damage by LGE remained stable in both groups over 2 years. Eplerenone offers effective and safe cardioprotection for boys with DMD, particularly when started at a younger age. Eplerenone is a useful clinical therapeutic option, particularly if treatment is initiated earlier in life when cardiac damage is minimal.en_US
dc.description.urihttps://doi.org/10.1186/s13023-017-0590-8
dc.language.isoen_USen_US
dc.publisherSpringer Natureen_US
dc.subjectCardiomyopathyen_US
dc.subjectEplerenoneen_US
dc.subjectMineralocorticoid receptor antagonisten_US
dc.subjectDuchenneen_US
dc.subjectMuscular dystrophyen_US
dc.titleEplerenone for early cardiomyopathy in Duchenne muscular dystrophy: results of a two-year open-label extension trialen_US
dc.typeArticleen_US
dc.relation.isAvailableAtEpidemiology & Biostatistics
dc.relation.isAvailableAtSchool of Public Health
dc.relation.isAvailableAtDigital Repository at the University of Maryland (DRUM)
dc.relation.isAvailableAtUniversity of Maryland (College Park, MD)


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record